A Clinical Study of SI-B001 in Combination With Paclitaxel in the Treatment of Recurrent and Metastatic HNSCC
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
Main purpose:
1. To evaluate the efficacy of SI-B001 monotherapy RP2D in combination with paclitaxel in
patients with locally advanced or metastatic head and neck squamous cell carcinoma
(non-nasopharyngeal carcinoma) obtained in phase I clinical trials.
2. To evaluate the safety and tolerability of SI-B001 monotherapy RP2D in combination with
paclitaxel in patients with locally advanced or metastatic head and neck squamous cell
carcinoma (non-nasopharyngeal carcinoma) obtained in phase I clinical trials.
Secondary purpose:
1. To evaluate the PK/PD of the research drug SI-B001 in combination with paclitaxel.
2. To evaluate the immunogenicity of SI-B001.